Venomyx Therapeutics on Wefunder

EpiPen for snakebites: the antivenom of tomorrow!

Raise to date: $297,421

Reporting Date: 07/31/2019

Key Stats

Minimum Raise

$50,000

Maximum Raise

$1,070,000

Likelihood of Max Unlikely
Start Date

03/14/2019

Stop Date

07/03/2019

Days Remaining

19999876

Security Type

SAFE

Investment Minimum

$100

Deal Type

No Review


Investment Summary

Status

Confirmed Closed

# of Investors

506

% of Minimum Raised

595%

% of Maximum Raised

28%

Dollars Per Day to Reach Max

N/A

DPD* Committed

$2,679

DPD* Category

$2,208

DPD* All Companies

$1,085

Kingscrowd Momentum

$297,421

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Venomyx Therapeutics, with a valuation cap of $5 million, is raising crowdfunding on WeFunder. The company is developing Vipax, the world’s first broad-spectrum antivenom for snakebites. The product is ten times more effective than traditional antivenoms and much cheaper. Venomyx Therapeutics was founded by Daniel Dempsey and Deepankar Roy. The proceeds of the current crowdfunding round, with a minimum raise of $50,000, will be used to complete the preclinical trials, file an application to the FDA, and finish the research. Venomyx Therapeutics is expected to be a revolution while using biotechnology, and not animals, for the production of antivenom.

INVEST NOW